The global antidepressant drugs market size was valued at USD 15,651.0 Million in 2020, and is projected to reach USD 21,004.8 Million by 2030, registering a CAGR of 3.0% from 2021 to 2030. Antidepressants drugs are a class of drugs that helps to relieve depression symptoms. Major depressive disorder is a global health crisis and has become the leading cause of disability, affecting over 300 million people worldwide.
The COVID-19 outbreak is anticipated to have a positive impact on growth of the global antidepressant drugs market. The COVID-19 pandemic has stressed healthcare systems in the world and increased the need for advanced hospitals. Implementation of the spread of COVID-19 infection increased the fear of social isolation, and loneliness, which is the main reason for major depressive disorders.
Antidepressant drugs act by increasing levels of excitatory neurotransmitters or nerve cell chemicals that act as messengers in nervous system. These drugs are also use to treat a wide range of conditions, such as generalized anxiety disorder, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD). It is also used for treatment of people with chronic pains. Antidepressant drugs may be prescribed as a first-line treatment for depression or in conjunction with other methods of controlling depression, such as behavioral therapy and exercise.
The global market for the antidepressant drugs is primarily driven by increase in prevalence of depression, rise in awareness regarding depression, and advancements in R&D activities in the healthcare sector drive the market. According to the World Health Organization (WHO), in 2021, it was reported that around 5% of adult are diagnose with depression. Antidepressant drugs act by maintaining the balance of various hormones and chemicals in the brain.
Major factors that contribute toward growth of the antidepressant drugs market is increase in prevalence of life-threatening diseases such as major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, and panic disorder. Moreover, rise in geriatric population and higher adoption of antidepressant drugs drive growth of the market. Furthermore, increase in number of approvals for antidepressant drugs drive growth of the market. For instance, in May 2020, Food and Drug Administration (FDA) announced the approval of Tauvid, which is an antidepressant drug used for treatment of patients with Alzheimer disease.
In addition, increase in number of clinical studies for evaluating safety and efficiency of a wide range of therapeutic drugs is anticipated to contribute toward growth of the market. For instance, in January 2022, Pacific Neuroscience Institute (PNI), announced the launch of psilocybin clinical trial for depression. This study aims to analyze safety and efficacy of psilocybin for treatment of major depressive disorders.
Moreover, according to the U.S. National Library of Medicine (NIH), it was reported that randomized placebo controlled clinical trial are conducted on fluvoxamine, which is an antidepressant drugs to analyze the effect on COVID-19 infection. It was analyzed that fluvoxamine is beneficial to reduce the risk of hospitalization & death rate by COVID-19 patients.
Furthermore, technological development in the pharmaceutical industry to manufacture advanced antidepressant drugs is expected to provide remunerative opportunities for expansion of the global antidepressant drugs market during the forecast period. Moreover, presence of key manufacturing companies to manufacture antidepressant drugs propel growth of the market.
In addition, initiatives taken by governments and private organizations to develop the pharmaceutical industry propel growth of the market. However, the side effect of antidepressant drugs such as feeling agitated, anxious, constipation, dizziness, and headache is expected to restrict the antidepressant drugs market growth during the forecast period.
The global antidepressant drugs market is segmented on the basis of product, depressive disorder, and region. By product, the market is categorized into tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist & reuptake inhibitors, and others.
On the basis of depressive disorder, it is divided into major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, and others.
Region wise, the antidepressant drugs market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Depending on product, the selective serotonin reuptake inhibitors segment dominated the antidepressant drugs market in 2020, and this trend is expected to continue during the forecast period, owing to advancements in R&D activities in the healthcare sector and increase in prevalence of major depressive disorder and anxiety disorders. However, the serotonin norepinephrine reuptake inhibitors segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of chronic neuropathic pain, and obsessive–compulsive disorder (OCD).
By depressive disorder, the major depressive disorder segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in prevalence of major depressive disorder and initiatives taken by governments and private organizations about development of drugs. However, the obsessive-compulsive disorder segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of mental disorder and increase in number of approval for anxiety drugs.
North America garnered a major share in the antidepressant drugs market in 2020, and is expected to continue to dominate during the forecast period, owing to rise in prevalence of depression disorder, increase in number of approval for antidepressant drugs, presence of key players, and development in R&D activities in the healthcare sector in the region. However, Asia-Pacific is expected to register highest CAGR of 4.9% from 2021 to 2030, owing to increase in prevalence of mental disorder, rise in awareness regarding depression, growth in health care expenditures, and increase in number of clinical trials.
The key players operating in the global antidepressant drugs market include Alkermes Plc, AbbVie Inc., Eli Lilly And Company, GlaxoSmithKline, Inc., H. Lundbeck A/S, Merck KGAA, Pfizer Inc., Teva Pharmaceutical Industries Ltd. (Actavis Generics), and Takeda Pharmaceutical Limited Company.
| Report Metric |
Details |
| Report Name |
Antidepressant Drugs Market |
| Market size value in 2020 |
USD 15,651.0 Million |
| Revenue forecast in 2030 |
USD 21,004.8 Million |
| Growth Rate |
3% |
| Base year considered |
2020 |
| Forecast Period |
2021-2030 |
| By Product |
Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist & Reuptake Inhibitors |
| By Depressive Disorder |
Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder |
| Report Coverage |
Revenue & volume forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered |
By Type, Application, and Region |
| Geographic Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Ans. The global antidepressant drugs market size was valued at $15,651.0 million in 2020, and is projected to reach $21,004.8 million by 2030, registering a CAGR of 3.0% from 2021 to 2030.
Ans. The key players operating in the global antidepressant drugs market include Alkermes Plc, AbbVie Inc., Eli Lilly And Company, GlaxoSmithKline, Inc., H. Lundbeck A/S, Merck KGAA, Pfizer Inc., Teva Pharmaceutical Industries Ltd. (Actavis Generics), and Takeda Pharmaceutical Limited Company.
Ans. Yes, the report includes a COVID-19 impact analysis. Also, it is further extended into every individual segment of the report.
CHAPTER 1:INTRODUCTION
1.1.Report Description
1.2.Key Market Segments
1.3.Key Benefits
1.4.Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO Perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market Definition and Scope
3.2.Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3.Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4.Market Share Analysis/Top Player Positioning
3.4.1. Market Share Analysis/Top Player Positioning 2020
3.5.Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis
CHAPTER 4:ANTIDEPRESSANT DRUGS MARKET, BY DEPRESSIVE DISORDER
4.1.Market Overview
4.1.1Market Size and Forecast, By Depressive Disorder
4.2. Major Depressive Disorder
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Obsessive Compulsive Disorder
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Generalized Anxiety Disorder
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Panic Disorder
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
4.6. Others
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, By Region
4.6.3. Market Share Analysis, By Country
CHAPTER 5:ANTIDEPRESSANT DRUGS MARKET, BY PRODUCT
5.1.Market Overview
5.1.1Market Size and Forecast, By Product
5.2. Selective Serotonin Reuptake Inhibitors
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Serotonin Norepinephrine Reuptake Inhibitors
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Monoamine Oxidase Inhibitors
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
5.5. Serotonin Antagonist and Reuptake Inhibitors
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, By Region
5.5.3. Market Share Analysis, By Country
5.6. Others
5.6.1. Key Market Trends, Growth Factors and Opportunities
5.6.2. Market Size and Forecast, By Region
5.6.3. Market Share Analysis, By Country
5.7. Tricyclic Antidepressants
5.7.1. Key Market Trends, Growth Factors and Opportunities
5.7.2. Market Size and Forecast, By Region
5.7.3. Market Share Analysis, By Country
CHAPTER 6:ANTIDEPRESSANT DRUGS MARKET, BY REGION
6.1.Market Overview
6.1.1Market Size and Forecast, By Region
6.2.Asia-Pacific
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Depressive Disorder
6.2.3. Market Size and Forecast, By Product
6.2.4. Market Size and Forecast, By Country
6.2.5. China Antidepressant Drugs Market
6.2.5.1. Market Size and Forecast, By Depressive Disorder
6.2.5.2. Market Size and Forecast, By Product
6.2.6. Japan Antidepressant Drugs Market
6.2.6.1. Market Size and Forecast, By Depressive Disorder
6.2.6.2. Market Size and Forecast, By Product
6.2.7. India Antidepressant Drugs Market
6.2.7.1. Market Size and Forecast, By Depressive Disorder
6.2.7.2. Market Size and Forecast, By Product
6.2.8. South Korea Antidepressant Drugs Market
6.2.8.1. Market Size and Forecast, By Depressive Disorder
6.2.8.2. Market Size and Forecast, By Product
6.2.9. Australia Antidepressant Drugs Market
6.2.9.1. Market Size and Forecast, By Depressive Disorder
6.2.9.2. Market Size and Forecast, By Product
6.2.10. Rest of Asia Pacific Antidepressant Drugs Market
6.2.10.1. Market Size and Forecast, By Depressive Disorder
6.2.10.2. Market Size and Forecast, By Product
6.3.LAMEA
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Depressive Disorder
6.3.3. Market Size and Forecast, By Product
6.3.4. Market Size and Forecast, By Country
6.3.5. Brazil Antidepressant Drugs Market
6.3.5.1. Market Size and Forecast, By Depressive Disorder
6.3.5.2. Market Size and Forecast, By Product
6.3.6. South Africa, Antidepressant Drugs Market
6.3.6.1. Market Size and Forecast, By Depressive Disorder
6.3.6.2. Market Size and Forecast, By Product
6.3.7. Saudi Arabia Antidepressant Drugs Market
6.3.7.1. Market Size and Forecast, By Depressive Disorder
6.3.7.2. Market Size and Forecast, By Product
6.3.8. Rest of LAMEA Antidepressant Drugs Market
6.3.8.1. Market Size and Forecast, By Depressive Disorder
6.3.8.2. Market Size and Forecast, By Product
6.4.North America
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Depressive Disorder
6.4.3. Market Size and Forecast, By Product
6.4.4. Market Size and Forecast, By Country
6.4.5. United States Antidepressant Drugs Market
6.4.5.1. Market Size and Forecast, By Depressive Disorder
6.4.5.2. Market Size and Forecast, By Product
6.4.6. Canada Antidepressant Drugs Market
6.4.6.1. Market Size and Forecast, By Depressive Disorder
6.4.6.2. Market Size and Forecast, By Product
6.4.7. Mexico Antidepressant Drugs Market
6.4.7.1. Market Size and Forecast, By Depressive Disorder
6.4.7.2. Market Size and Forecast, By Product
6.5.Europe
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Depressive Disorder
6.5.3. Market Size and Forecast, By Product
6.5.4. Market Size and Forecast, By Country
6.5.5. Germany Antidepressant Drugs Market
6.5.5.1. Market Size and Forecast, By Depressive Disorder
6.5.5.2. Market Size and Forecast, By Product
6.5.6. France Antidepressant Drugs Market
6.5.6.1. Market Size and Forecast, By Depressive Disorder
6.5.6.2. Market Size and Forecast, By Product
6.5.7. U.K Antidepressant Drugs Market
6.5.7.1. Market Size and Forecast, By Depressive Disorder
6.5.7.2. Market Size and Forecast, By Product
6.5.8. Italy Antidepressant Drugs Market
6.5.8.1. Market Size and Forecast, By Depressive Disorder
6.5.8.2. Market Size and Forecast, By Product
6.5.9. Spain Antidepressant Drugs Market
6.5.9.1. Market Size and Forecast, By Depressive Disorder
6.5.9.2. Market Size and Forecast, By Product
6.5.10. Rest of Europe Antidepressant Drugs Market
6.5.10.1. Market Size and Forecast, By Depressive Disorder
6.5.10.2. Market Size and Forecast, By Product
CHAPTER 7:COMPANY PROFILES
7.1. Alkermes Plc.
7.1.1.Company Overview
7.1.2.Key Executives
7.1.3.Company snapshot
7.1.4.Operating business segments
7.1.5.Product portfolio
7.1.6.Business Performance
7.1.7.Key Strategic Moves and Developments
7.2. AbbVie Inc.
7.2.1.Company Overview
7.2.2.Key Executives
7.2.3.Company snapshot
7.2.4.Operating business segments
7.2.5.Product portfolio
7.2.6.Business Performance
7.2.7.Key Strategic Moves and Developments
7.3. Eli Lilly and Company
7.3.1.Company Overview
7.3.2.Key Executives
7.3.3.Company snapshot
7.3.4.Operating business segments
7.3.5.Product portfolio
7.3.6.Business Performance
7.3.7.Key Strategic Moves and Developments
7.4. GlaxoSmithKline, Inc.
7.4.1.Company Overview
7.4.2.Key Executives
7.4.3.Company snapshot
7.4.4.Operating business segments
7.4.5.Product portfolio
7.4.6.Business Performance
7.4.7.Key Strategic Moves and Developments
7.5. H. Lundbeck A S
7.5.1.Company Overview
7.5.2.Key Executives
7.5.3.Company snapshot
7.5.4.Operating business segments
7.5.5.Product portfolio
7.5.6.Business Performance
7.5.7.Key Strategic Moves and Developments
7.6. F. Hoffmann-La Roche Ltd
7.6.1.Company Overview
7.6.2.Key Executives
7.6.3.Company snapshot
7.6.4.Operating business segments
7.6.5.Product portfolio
7.6.6.Business Performance
7.6.7.Key Strategic Moves and Developments
7.7. Merck KGAA
7.7.1.Company Overview
7.7.2.Key Executives
7.7.3.Company snapshot
7.7.4.Operating business segments
7.7.5.Product portfolio
7.7.6.Business Performance
7.7.7.Key Strategic Moves and Developments
7.8. Pfizer Inc.
7.8.1.Company Overview
7.8.2.Key Executives
7.8.3.Company snapshot
7.8.4.Operating business segments
7.8.5.Product portfolio
7.8.6.Business Performance
7.8.7.Key Strategic Moves and Developments
7.9. Teva Pharmaceutical Industries Ltd
7.9.1.Company Overview
7.9.2.Key Executives
7.9.3.Company snapshot
7.9.4.Operating business segments
7.9.5.Product portfolio
7.9.6.Business Performance
7.9.7.Key Strategic Moves and Developments
7.10. Takeda Pharmaceutical Limited Company
7.10.1.Company Overview
7.10.2.Key Executives
7.10.3.Company snapshot
7.10.4.Operating business segments
7.10.5.Product portfolio
7.10.6.Business Performance
7.10.7.Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1.GLOBAL ANTIDEPRESSANT DRUGS MARKET, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 2.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR MAJOR DEPRESSIVE DISORDER, BY REGION, 2020-2030 ($MILLION)
TABLE 3.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR OBSESSIVE COMPULSIVE DISORDER, BY REGION, 2020-2030 ($MILLION)
TABLE 4.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR GENERALIZED ANXIETY DISORDER, BY REGION, 2020-2030 ($MILLION)
TABLE 5.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR PANIC DISORDER, BY REGION, 2020-2030 ($MILLION)
TABLE 6.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 7.GLOBAL ANTIDEPRESSANT DRUGS MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 8.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2020-2030 ($MILLION)
TABLE 9.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2020-2030 ($MILLION)
TABLE 10.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR MONOAMINE OXIDASE INHIBITORS, BY REGION, 2020-2030 ($MILLION)
TABLE 11.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS, BY REGION, 2020-2030 ($MILLION)
TABLE 12.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 13.GLOBAL ANTIDEPRESSANT DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2020-2030 ($MILLION)
TABLE 14.GLOBAL ANTIDEPRESSANT DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 15.ASIA-PACIFIC ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 16.ASIA-PACIFIC ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 17.CHINA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 18.CHINA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 19.JAPAN ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 20.JAPAN ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 21.INDIA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 22.INDIA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 23.SOUTH KOREA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 24.SOUTH KOREA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 25.AUSTRALIA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 26.AUSTRALIA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 27.REST OF ASIA PACIFIC ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 28.REST OF ASIA PACIFIC ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 29.LAMEA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 30.LAMEA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 31.BRAZIL ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 32.BRAZIL ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 33.SOUTH AFRICA, ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 34.SOUTH AFRICA, ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 35.SAUDI ARABIA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 36.SAUDI ARABIA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 37.REST OF LAMEA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 38.REST OF LAMEA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 39.NORTH AMERICA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 40.NORTH AMERICA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 41.UNITED STATES ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 42.UNITED STATES ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 43.CANADA ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 44.CANADA ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 45.MEXICO ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 46.MEXICO ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 47.EUROPE ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 48.EUROPE ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 49.GERMANY ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 50.GERMANY ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 51.FRANCE ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 52.FRANCE ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 53.UNITED KINGDOM ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 54.UNITED KINGDOM ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 55.ITALY ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 56.ITALY ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 57.SPAIN ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 58.SPAIN ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 59.REST OF EUROPE ANTIDEPRESSANT DRUGS, BY DEPRESSIVE DISORDER, 2020-2030 ($MILLION)
TABLE 60.REST OF EUROPE ANTIDEPRESSANT DRUGS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 61.ALKERMES PLC: KEY EXECUTIVES
TABLE 62.ALKERMES PLC: COMPANY SNAPSHOT
TABLE 63.ALKERMES PLC: OPERATING SEGMENTS
TABLE 64.ALKERMES PLC: PRODUCT PORTFOLIO
TABLE 65.ALKERMES PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 66.ABBVIE INC.: KEY EXECUTIVES
TABLE 67.ABBVIE INC.: COMPANY SNAPSHOT
TABLE 68.ABBVIE INC.: OPERATING SEGMENTS
TABLE 69.ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 70.ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 71.ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 72.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 73.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 74.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 75.ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 76.GLAXOSMITHKLINE, INC: KEY EXECUTIVES
TABLE 77.GLAXOSMITHKLINE, INC: COMPANY SNAPSHOT
TABLE 78.GLAXOSMITHKLINE, INC: OPERATING SEGMENTS
TABLE 79.GLAXOSMITHKLINE, INC: PRODUCT PORTFOLIO
TABLE 80.GLAXOSMITHKLINE, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 81.H. LUNDBECK A S: KEY EXECUTIVES
TABLE 82.H. LUNDBECK A S: COMPANY SNAPSHOT
TABLE 83.H. LUNDBECK A S: OPERATING SEGMENTS
TABLE 84.H. LUNDBECK A S: PRODUCT PORTFOLIO
TABLE 85.H. LUNDBECK A S: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 86.F. HOFFMANN-LA ROCHE LTD: KEY EXECUTIVES
TABLE 87.F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 88.F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
TABLE 89.F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 90.F. HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 91.MERCK KGAA: KEY EXECUTIVES
TABLE 92.MERCK KGAA: COMPANY SNAPSHOT
TABLE 93.MERCK KGAA: OPERATING SEGMENTS
TABLE 94.MERCK KGAA: PRODUCT PORTFOLIO
TABLE 95.MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 96.PFIZER INC: KEY EXECUTIVES
TABLE 97.PFIZER INC: COMPANY SNAPSHOT
TABLE 98.PFIZER INC: OPERATING SEGMENTS
TABLE 99.PFIZER INC: PRODUCT PORTFOLIO
TABLE 100.PFIZER INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101.TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
TABLE 102.TEVA PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
TABLE 103.TEVA PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS
TABLE 104.TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
TABLE 105.TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 106.TAKEDA PHARMACEUTICAL LIMITED COMPANY: KEY EXECUTIVES
TABLE 107.TAKEDA PHARMACEUTICAL LIMITED COMPANY: COMPANY SNAPSHOT
TABLE 108.TAKEDA PHARMACEUTICAL LIMITED COMPANY: OPERATING SEGMENTS
TABLE 109.TAKEDA PHARMACEUTICAL LIMITED COMPANY: PRODUCT PORTFOLIO
TABLE 110.TAKEDA PHARMACEUTICAL LIMITED COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1.GLOBAL ANTIDEPRESSANT DRUGS MARKET SEGMENTATION
FIGURE 2.GLOBAL ANTIDEPRESSANT DRUGS MARKET
FIGURE 3.SEGMENTATION ANTIDEPRESSANT DRUGS MARKET
FIGURE 4.TOP INVESTMENT POCKET IN ANTIDEPRESSANT DRUGS MARKET
FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
FIGURE 11.LOW THREAT OF SUBSTITUTION
FIGURE 12.HIGH COMPETITIVE RIVALRY
FIGURE 13.TOP PLAYER POSITIONING, 2020
FIGURE 14.MARKET SHARE ANALYSIS, 2020
FIGURE 15.RESTRAINTS AND DRIVERS: ANTIDEPRESSANT DRUGS MARKET
FIGURE 16.ANTIDEPRESSANT DRUGS MARKET SEGMENTATION, BY DEPRESSIVE DISORDER
FIGURE 17.ANTIDEPRESSANT DRUGS MARKET FOR MAJOR DEPRESSIVE DISORDER, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 18.ANTIDEPRESSANT DRUGS MARKET FOR OBSESSIVE COMPULSIVE DISORDER, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 19.ANTIDEPRESSANT DRUGS MARKET FOR GENERALIZED ANXIETY DISORDER, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 20.ANTIDEPRESSANT DRUGS MARKET FOR PANIC DISORDER, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 21.ANTIDEPRESSANT DRUGS MARKET FOR OTHERS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 22.ANTIDEPRESSANT DRUGS MARKET SEGMENTATION, BY PRODUCT
FIGURE 23.ANTIDEPRESSANT DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 24.ANTIDEPRESSANT DRUGS MARKET FOR SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 25.ANTIDEPRESSANT DRUGS MARKET FOR MONOAMINE OXIDASE INHIBITORS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 26.ANTIDEPRESSANT DRUGS MARKET FOR SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 27.ANTIDEPRESSANT DRUGS MARKET FOR OTHERS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 28.ANTIDEPRESSANT DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 29.ALKERMES PLC: NET SALES, 2018-2020 ($MILLION)
FIGURE 30.ALKERMES PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 31.ALKERMES PLC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 32.ABBVIE INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 33.ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 34.ABBVIE INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 35.ELI LILLY AND COMPANY: NET SALES, 2018-2020 ($MILLION)
FIGURE 36.ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 37.ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 38.GLAXOSMITHKLINE, INC: NET SALES, 2018-2020 ($MILLION)
FIGURE 39.GLAXOSMITHKLINE, INC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 40.GLAXOSMITHKLINE, INC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 41.H. LUNDBECK A S: NET SALES, 2018-2020 ($MILLION)
FIGURE 42.H. LUNDBECK A S: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 43.H. LUNDBECK A S: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 44.F. HOFFMANN-LA ROCHE LTD: NET SALES, 2018-2020 ($MILLION)
FIGURE 45.F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 46.F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 47.MERCK KGAA: NET SALES, 2018-2020 ($MILLION)
FIGURE 48.MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 49.MERCK KGAA: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 50.PFIZER INC: NET SALES, 2018-2020 ($MILLION)
FIGURE 51.PFIZER INC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 52.PFIZER INC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 53.TEVA PHARMACEUTICAL INDUSTRIES LTD: NET SALES, 2018-2020 ($MILLION)
FIGURE 54.TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 55.TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 56.TAKEDA PHARMACEUTICAL LIMITED COMPANY: NET SALES, 2018-2020 ($MILLION)
FIGURE 57.TAKEDA PHARMACEUTICAL LIMITED COMPANY: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 58.TAKEDA PHARMACEUTICAL LIMITED COMPANY: REVENUE SHARE, BY REGION, 2020 (%)
$6168
$10663
HAVE A QUERY?
OUR CUSTOMER
SIMILAR REPORTS
Add to Cart
Add to Cart
Add to Cart
Add to Cart